Accurate diagnosis and treatment of tumors, one of the top global health problems, has always been the research focus of scientists and doctors. Near-infrared (NIR) emissive semiconducting polymers dots (Pdots) have demonstrated bright prospects in field of in vivo tumor fluorescence imaging owing to some of their intrinsic advantages, including good water-dispersibility, facile surface-functionalization, easily tunable optical properties, and good biocompatibility. During recent years, much effort has been devoted to developing Pdots with emission bands located in the second near-infrared (NIR-II, 1000-1700 nm) region, which hold great advantages of higher spatial resolution, better signal-to-background ratios (SBR), and deeper tissue penetration for solid-tumor imaging in comparison with the visible region (400-680 nm) and the first near-infrared (NIR-I, 680-900 nm) window, by virtue of the reduced tissue autofluorescence, minimal photon scattering, and low photon absorption. In this review, we mainly summarize the latest advances of NIR-II emissive semiconducting Pdots for in vivo tumor fluorescence imaging, including molecular engineering to improve the fluorescence quantum yields and surface functionalization to elevate the tumor-targeting capability. We also present several NIR-II theranostic Pdots used for integrated tumor fluorescence diagnosis and photothermal/photodynamic therapy. Finally, we give our perspectives on future developments in this field.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775418PMC
http://dx.doi.org/10.3390/bios12121126DOI Listing

Publication Analysis

Top Keywords

tumor fluorescence
16
emissive semiconducting
12
vivo tumor
12
fluorescence imaging
12
advances nir-ii
8
nir-ii emissive
8
fluorescence
5
semiconducting polymer
4
polymer dots
4
dots vivo
4

Similar Publications

Purpose: To validate the Axillary Reverse Mapping (ARM) technique with indocyanine green (ICG), focusing on the detection rate and the procedure's feasibility. The predictive factors for metastatic involvement of ARM nodes are also analyzed to define the target population for ARM indication.

Methods: This prospective, observational, non-randomized study of patients with breast cancer included patients with an indication for axillary lymph node dissection (ALND) performed between June 2021 and June 2023.

View Article and Find Full Text PDF

Colon cancer is a leading cause of cancer-related deaths worldwide and has been increasingly linked to the gut microbiome. Clostridium butyricum (CB), a probiotic, has demonstrated potential in influencing colon cancer cell behavior, particularly through the modulation of long non-coding RNAs (lncRNAs) and mRNAs. This study examines the effects of CB on the expression of lncRNAs and mRNAs in SW480 colon cancer cells and their association with apoptosis.

View Article and Find Full Text PDF

Functionalization of polymer nanoparticles (NPs) with targeting peptides is of interest for drug delivery applications to enhance tumor accumulation and penetration. Herein, we evaluated the feasibility of two different methods for the attachment of a tumor-penetrating peptide LinTT1 (AKRGARSTA) to poly(ethylene glycol)-block-poly(ε-caprolactone) (PCL-PEG) NPs: (1) "post-conjugation" onto pre-formed nanoparticles, and (2) "pre-conjugation", the synthesis and purification of peptide-polymer conjugates and subsequent nanoprecipitation of the conjugates diluted with non-functionalized polymers. Conjugation of the labelled peptide via maleimide-thiol chemistry was verified by gel permeation chromatography (GPC) and fluorescence measurements.

View Article and Find Full Text PDF

Donafenib is an improved version of sorafenib in which deuterium is substituted into the drug's chemical structure, enhancing its stability and antitumor activity. Donafenib exhibits enhanced antitumor activity and better tolerance than sorafenib in preclinical and clinical studies. However, the specific mechanism of its effect on hepatocellular carcinoma has not been reported.

View Article and Find Full Text PDF

Despite the favorable effects of immunotherapies in multiple types of cancers, its complete success in CNS malignancies remains challenging. Recently, a successful clinical trial of cytokine-induced killer (CIK) cell immunotherapy in patients with glioblastoma (GBM) has opened a new avenue for adoptive cellular immunotherapies in CNS malignancies. Prompt from these findings, herein, we investigated whether dendritic cells (DC) in combination with cytokine-induced killer cells (DC-CIK) could also provide an alternative and more effective way to improve the efficacy of GBM treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!